Alport syndrome and thin basement membrane nephropathy

Nephron - Clinical Practice

Volumn 106, Issue 2, 2007, Pages

  Thorner, Paul Scott ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alport syndrome; Glomerular basement membrane; Thin basement membrane; Type IV collagen

Indexed keywords

ADENOVIRUS VECTOR; CHEMOKINE RECEPTOR ANTAGONIST; COLLAGEN TYPE 4; COLLAGEN TYPE 4 ALPHA5; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE; GELATINASE A; MACROPHAGE ELASTASE; METALLOPROTEINASE INHIBITOR; PROTEIN SUBUNIT; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ANTAGONIST; TUMSTATIN; UNCLASSIFIED DRUG;

ALPORT SYNDROME; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW TRANSPLANTATION; DIAGNOSTIC TEST; DISEASE COURSE; ELECTRON MICROSCOPY; EYE DISEASE; FAMILY HISTORY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HEARING LOSS; HEMATURIA; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; STEM CELL GENE THERAPY; THIN BASEMENT MEMBRANE NEPHROPATHY; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME LINKED DISORDER;

GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; NEPHRITIS, HEREDITARY;

EID: 34250630898     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101802     Document Type: Article

References (26)

1. Hudson B: The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004;15:2514-2527.
2. Miner J, Sanes J: Collagen IV α3, α4, and α5 chains in rodent basal laminae: sequence, distribution, association with laminins, and developmental switches. J Cell Biol 1994;127:879-891.
3. Kalluri R, Shield F, Todd P, Hudson B, Neilson E: Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997;99:2470-2478.
4. Harvey S, Zheng K, Sado Y, Naito I, Ninomiya Y, Jacobs R, et al: The role of distinct type IV collagen networks in glomerular development and function. Kidney Int 1998;54:1857-1866.
5. Harvey S, Mount R, Sado Y, Naito I, Ninomiya Y, Jefferson B, et al: The inner ear of dogs with X-linked nephritis provides clues to the pathogenesis of hearing loss in X-linked Alport syndrome. Am J Pathol 2001;159:1097-1104.
6. Kashtan C: Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998;9:1736-1750.
7. Jais J, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, et al: X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000;11:649-657.
8. Longo I, Porcedda P, Mari F, Giachino D, Meloni I, Deplano C, et al: COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 2002;61:1947-1956.
9. Pescucci C, Mari F, Longo I, Vogiatzi P, Caselli R, Scala E, et al: Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 2004;65:1598-1603.
10. Heath K, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson L, Savige J, et al: Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001;69:1033-1045.
11. Jais J, Knebelmann B, Giatras I, de Marchi M, Rizzoni G, Renieri A, et al: X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A 'European Community Alport Syndrome Concerted Action' study. J Am Soc Nephrol 2003;14:2603-2610.
12. Gubler M-C, Knebelmann B, Beziau A, Broyer M, Pirson Y, Haddoum F, et al: Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution. Kidney Int 1995;47:1142-1147.
13. Rao V, Meehan D, Delimont D, Nakajima M, Wada T, Gratton M, et al: Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. Am J Pathol 2006;169:32-46.
14. Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, et al: Integrin α1β1 and transforming growth factor-β1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 2000;157:1649-1659.
15. Rao V, Lees G, Kashtan C, Nemori R, Singh R, Meehan D, et al: Increased expression of MMP-2, MMP-9 (type IV collagenases/gelatinases), and MT1-MMP in canine X-linked Alport syndrome (XLAS). Kidney Int 2003;63:1736-1748.
16. Greer K, Higgins M, Cox M, Ryan T, Berridge B, Kashtan C, et al: Gene expression analysis in a canine model of X-linked Alport syndrome. Mammalian Genome 2006;17:976-990.
17. Cosgrove D, Samuelson G, Meehan D, Miller C, McGee J, Walsh E, et al: Ultrastructural, physiological, and molecular defects in the inner ear of a gene-knockout mouse model for autosomal Alport syndrome. Hearing Res 1998;121:84-98.
18. Merchant S, Burgess B, Adams J, Kashtan C, Gregory M, Santi P, et al: Temporal bone histopathology in Alport syndrome. Laryngoscope 2004;114:1609-1618.
19. Ohkubo S, Takeda H, Higashide T, Ito M, Sakurai M, Shirao Y, et al: Immunohistochemical and molecular genetic evidence for type IV collagen α5 chain abnormality in the anterior lenticonus associated with Alport syndrome. Arch Ophthalmol 2003;121:846-850.
20. Kalluri R, Torre A, Shield C, Zamborsky E, Werner M, Suchin E, et al: Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport post-transplant anti-glomerular basement membrane antibodies. Transplantation 2000;69:679-683.
21. Callis L, Vila A, Carrera M, Nieto J: Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 1999;55:1051-1056.
22. Chen D, Jefferson B, Harvey S, Zheng K, Gartley C, Jacobs R, et al: Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol 2003;14:690-698.
23. Charbit M, Gubler M, Dechaux M, Gagnadoux M, Grunfeld J, Niaudet P: Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007;22:57-63.
24. Proesmans W, Knockaert H, Trouet D: Enalapril in paediatric patients with Alport syndrome: 2 years' experience. Eur J Pediatr 2000;159:430-433.
25. Grodecki K, Gains M, Baumal R, Osmond D, Cotter B, Valli V, et al: Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comparative Pathol 1997;117:209-225.
26. Gross O, Schulze-Lohoff E, Koepke M, Beirowski B, Addicks K, Bloch W, et al: Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004;19:1716-1723.